<DOC>
	<DOCNO>NCT02527707</DOCNO>
	<brief_summary>A phase 2 , open-label study evaluate safety , tolerability , pharmacokinetics , pharmacodynamic activity titrating-dose lonafarnib combination ritonavir patient chronically infect hepatitis delta virus</brief_summary>
	<brief_title>Titrating-Dose Lonafarnib Combination With Ritonavir</brief_title>
	<detailed_description>This Phase 2 study 24 week treatment dose-titration regimen lonafarnib/ritonavir 15 patient chronically infected HDV : lonafarnib start 50 mg bid combination ritonavir ( 100 mg bid ) escalate lonafarnib tolerate . The duration study patient approximately 13 month ( 4 week screen , 24 week treatment , 4 week primary follow-up visit , monthly safety follow-up visit 5 month thereafter ) . The 6-month follow-up last dose study drug design allow evaluation clinical virologic course completion 24-week Treatment Period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Key 1 . Male female , 18 65 year age , inclusive 2 . Chronic HDV infection document positive HDV antibody ( Ab ) test least 6 month duration detectable HDV RNA qPCR study entry 3 . Liver biopsy demonstrate evidence chronic hepatitis 4 . Willingness practice appropriate contraception Key 1 . Previous use lonafarnib 2 . Coinfected HIV HCV 3 . Active jaundice define total bilirubin level &gt; 2.0 mg/dL know Gilbert 's disease 4 . Decompensated liver disease cirrhosis , history bleed esophageal varix , ascites , hepatic encephalopathy 5 . Serum creatinine concentration â‰¥1.5 time upper limit normal ( ULN ) 6 . Evidence another form viral hepatitis another form liver disease 7 . Evidence hepatocellular carcinoma 8 . Use alpha interferon , either interferon alfa2a interferon alfa2b , pegylated interferon alfa2a within 2 month start screen 9 . Concomitant use following : 1 . Medications food know moderate strong inducer inhibitor CYP3A4 CYP2C19 2 . Drugs know prolong PR QT interval 3 . Receipt systemic immunosuppressive therapy within 3 month start screen 4 . Statins , due inhibition mevalonate synthesis , reduce protein prenylation 5 . Medications contraindicate prescribe information ritonavir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>